• Tuesday, October 22nd
  • like us on facebook
  • like us on facebook


Bioniche, dissident shareholders reach deal

Agreement ends proxy battle, board of directors to be peacefully revamped, founder and CEO Graeme McRae will step down… Read on: globeandmail – Report on Business


Metro to close some Ontario stores, partner with Target in Quebec

MONTREAL — Metro is reorganizing its Ontario grocery store network and will become the exclusive operator of Target’s pharmacies in Quebec as it continues to adjust to intense competition and dramatic changes in the Canadian supermarket...


A prescription for drugstore investors

Loblaw’s bid for Shoppers highlights the appeal of the pharmacy business. But the best values may lie south of the border… Read on: globeandmail – Report on Business


Valeant to buy Bausch & Lomb for $8.7-billion

Valeant to buy Bausch & Lomb for $8.7-billion

Valeant Pharmaceuticals International Inc. has struck a deal to acquire eye-care company Bausch _ Lomb Inc. for $8.7-billion (U.S.) in cash. There were reports last week that Laval, Que.-based Valeant was in talks to buy Bausch _ Lomb… Read...


Health care stocks: As boomers age, a booming sector emerges

For the next 18 years, 8,800 Americans will turn 65 every single day. According to the Health Care Cost Institute, they will each spend $ 142,000 (U.S.) in medical expenses over the next 20 years. My colleague Rob Belanger and I thought it...


Coke promotes diet drink option

Coca-Cola says it will work to make lower-calorie drinks and clear nutrition information more widely available . Diet drinks are not always available in emerging markets such as China . A spokesman says the goal is to have diet options available...


Danish drug maker Novo Nordisk Q1 net profits up 28 per cent on strong sales of diabetic drugs

COPENHAGEN – Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit rose 28 per cent on strong sales of its diabetic drugs. The world’s largest insulin maker said net profit in the first three months of 2013...


Shoppers Drug Mart revenue up on over-the-counter sales

(Reuters) – Shoppers Drug Mart Corp, Canada’s biggest pharmacy chain, reported a 4 percent rise in first-quarter revenue as higher over-the-counter sales helped to offset tighter price controls for generics. The price controls, which...


Can robust returns for health-care stocks be sustained?

The CI Global Health Sciences fund led the way with a first-quarter return of 20 per cent and an annual return of 44 per cent. Fund manager Andrew Waight attributes the sector’s strength to a mix of factors including a lack of options...


Top mutual funds investing in health care

Top mutual funds investing in health care

That’s certainly the case for CI Global Health Sciences Corporate Class, which claimed the top spot in the screen with a return of nearly 44 per cent for the year ended March 31. The fund has a broad mandate to invest in global companies...


Calgary company’s technology puts diagnostic imaging in the palm of a hand

Calgary company’s technology puts diagnostic imaging in the palm of a hand

CALGARY – A Calgary company that was one of the first to recognize the medical applications of the mobile revolution has hit another milestone. Calgary Scientific Inc. recently became the first company to receive U.S. FDA approval for...


Roche signs $392 million Huntington’s pact with Isis

Roche signs $ 392 million Huntington’s pact with Isis PharmaTimes World News


Top Pharma Companies by 2012 Revenues

In the annals of Big Pharma, 2012 was expected to be the year of all patent-cliff years. With more than a dozen patent expirations, it was the year most dreaded by much of Big Pharma. Yes, the biggest blockbuster lost patent protection in 2011–Pfizer's...


Johnson _ Johnson recalls blood sugar meters because of risky malfunction

Blood glucose meters made by Johnson _ Johnson are being recalled in North America because they do not provide a warning when a diabetic’s blood sugar level is dangerously high globeandmail – Health & Fitness


Strategy: Why Big Pharmas Do What They Do — And How Silicon Valley Might Help Them Think Differently

AstraZeneca’s revitalization strategy, announced this week, follows the same well-worn playbook used by so many in the industry, employing approaches vividly familiar from my consulting days: cut headcount, externalize R_D, focus on...